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Abstract
Background: Oxidative stress is associated with the pathogenesis of cigarette smoke related lung
diseases, but longitudinal effects of smoking cessation on oxidant markers in the airways are
unknown.
Methods: This study included 61 smokers; 21 with chronic bronchitis or COPD, 15 asthmatics
and 25 asymptomatic smokers followed up for 3 months after smoking cessation. Fractional
exhaled nitric oxide (FeNO), sputum neutrophil counts, sputum 8-isoprostane, nitrotyrosine and
matrix metalloproteinase-8 (MMP-8) were investigated at baseline and 1 and 3 months after
smoking cessation.
Results: After 3 months 15 subjects had succeeded in quitting of smoking and in these subjects
symptoms improved significantly. Unexpectedly, however, sputum neutrophils increased (p =
0.046) after smoking cessation in patients with chronic bronchitis/COPD. At baseline, the other
markers did not differ between the three groups so these results were combined for further
analysis. Sputum 8-isoprostane declined significantly during the follow-up at 3 months (p = 0.035),
but levels still remained significantly higher than in non-smokers. The levels of FeNO, nitrotyrosine
and MMP-8 did not change significantly during the 3 months after smoking cessation.
Conclusion: Whilst symptoms improve after smoking cessation, the oxidant and protease burden
in the airways continues for months.
Background
COPD is related to smoking in most of the cases [1] and
smoking cessation is the single most beneficial and cost-
effective way to reduce COPD morbidity, hospital admis-
sions[2] and COPD progression [1]. Given that as many
as 30% of asthmatics smoke [3], smoking is now also seen
as an important contributor to asthma pathogenesis.
Thus, smoking asthmatics tend to have more severe dis-
ease than non-smoking asthmatics, their inflammatory
features are different from those with typical asthma and
their symptoms and inflammation is relatively resistant to
corticosteroids [4]. Numerous cross-sectional studies have
been conducted on current smokers, ex-smokers and
COPD patients, while only a few longitudinal studies
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have assessed long-term effects of smoking cessation
[5,6]. Smoking asthmatics have generally been excluded
from most asthma studies.
Persistent inflammation in the airways of COPD patients
may continue after quitting smoking. Thus a recent study,
which analyzed pooled data from three bronchial biopsy
studies, concluded that numbers of airway inflammatory
cells, including CD4+ and CD8+ lymphocytes were largely
similar in current smokers and ex-smokers [7]. Another
longitudinal study showed persistence of raised sputum
neutrophils and lymphocytes even one year after smoking
cessation [6]. In contrast, asthmatics, who quit smoking for
six weeks, showed reduced numbers of sputum neutrophils
[5]. These studies suggest ongoing inflammation, at least in
COPD patients, after smoking cessation.
Little is known about the effects of smoking cessation on
any oxidant marker in the longitudinal setting. In previ-
ous cross-sectional studies [8,9], we have found signifi-
cant increases of several oxidant markers (such as 8-
isoprostane, inducible nitric oxide synthase and nitrotyro-
sine) in the sputum samples of asymptomatic smokers
when compared to never smokers and also higher marker
levels in COPD patients when compared with non-symp-
tomatic smokers. We have also found that the levels of
several markers of oxidative stress in induced sputum
were very similar in never smokers and healthy ex-smok-
ers who had quit smoking more than 20 years ago [8,9],
suggesting that oxidative stress declines with time after
stopping of smoking, although the speed at which these
improvements take place has remained unknown.
In the current study we have investigated whether smok-
ing cessation has rapid effects on sputum markers of oxi-
dative/nitrosative stress in exhaled air and sputum of
subjects with chronic bronchitis/COPD, asthma and
asymptomatic smokers during a period of 3 months after
quitting smoking. The chosen markers included 8-iso-
prostane, fractional nitric oxide (FeNO), and nitrotyro-
sine; to our knowledge, the effect of smoking cessation on
these markers is unknown. Matrix metalloproteinases
(MMPs) have been suggested to associate with the patho-
genesis of COPD and asthma [10-12] and their complex
activation can be triggered by increased oxidative stress
[13,14]. The effects of smoking cessation on MMPs are
also unknown. Based on our recent sputum studies of sev-
eral MMPs in mild COPD [15], we selected the analysis of
sputum MMP-8 for the current study.
Methods
Study design
This was a prospective study where subjects were recruited
from three different smoking cessation clinics: Helsinki Uni-
versity Central Hospital, Southampton University Hospitals
Trust (SUHT) and the "Quitters' specialist smoking cessation
service" of the Southampton and South West Hampshire
Region. Patients were examined prior to commencing the
smoking cessation programme and the effects of smoking
cessation on airway inflammation investigated in exhaled air
and sputum samples at baseline and 1 and 3 months after
successful cessation, which was confirmed by frequent
exhaled carbon monoxide analyses. The study was approved
by the Ethics Committees of Helsinki University Hospital
and the Southampton University Hospital. All subjects gave
full informed consent.
Subjects
Subjects were classified into three categories (Table 1): 1)
smokers with cough and sputum production but normal
spirometry (Stage 0 COPD in earlier GOLD classifica-
tion), referred to as chronic bronchitis (n = 7) in this
study, and smokers with varying severity of COPD (n =
14), all having FEV/FVC<70%), 2) smoking asthmatics
and 3) asymptomatic smoking subjects with normal lung
function (FEV/FVC>70%). None of the subjects in the first
and third groups were atopic according to skin prick tests
or had significant (>12%) bronchodilator reversibility.
Two of smokers with bronchitis/COPD were treated with
inhaled steroids (average dose 1200 μg/day) whereas all
asthmatic were treated with inhaled steroid (average dose
680 μg/day). The dose of inhaled steroids was kept stable
during the entire study.
Of the total of 61 subjects enrolled, only 6 smokers with
bronchitis/COPD, 6 subjects with asthma and 3 asympto-
matic smokers managed to quit smoking for 3 months.
Subjects who had not been successful at stopping smok-
Table 1: Subject characteristics
Non symptomatic Bronchitis/COPD Asthma
Number 25 21 15
Age, yr 41 (18–64) 56 (41–72) 42 (18–58)
Sex M/F 11/14 7/14 5/10
FEV1 (%pred) 97,8 (86–126) 76,8 (25–109) 95,6 (61–127)
FVC (%pred) 98,6 (40–124) 99 (50–203) 100,5 (36–139)
FEV1/FVC ratio% 82,6 (71–109) 66,7 (28–87) 76,6 (74–79)
DLCO/VA 87 (50–118) 53,3 (28–77) 85,4 (57–107)
Pack years 22 (4,5–60) 39 (17–75) 22 (6–48)BMC Pulmonary Medicine 2009, 9:25 http://www.biomedcentral.com/1471-2466/9/25
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ing also failed to keep follow-up appointments, leaving
the 15 subjects. The final analyses were conducted on the
quitters who also had produced good quality sputum
specimens. The number of the analyses was lower than
the total number of subjects who succeeded to quit smok-
ing due to unrepresentative sputum specimens during the
control visit. Respiratory symptoms and health status in
subjects were assessed with St Georges Respiratory Ques-
tionnaire (SGRQ) at baseline and at 1 and 3 months.
Flow-volume spirometry and diffusion capacity measure-
ment were conducted using standard methods [16].
Sputum induction and processing
Sputum induction was conducted in all centres using the
guidelines of the European Respiratory Society's Task Force
[17]; the same standard operation protocol has been
described in previous studies of our laboratory [8,9]. One
author (PR) participated to the processing in each centre.
Sputum was induced with 4.5% hypertonic saline given at 5-
min intervals for a maximum of 20 min, with mean induc-
tion times being similar in the three subject groups. The
mucoid components of sputum were selected in order to
reduce salivary contamination and processed as described
[18] with four volumes of dithioerythritol (DTE). DTE
improves cell and mediator recovery without causing cell
activation [19]. The suspensions were filtered through 70-
μm nylon gauze and centrifuged at 400 g at 4°C for 10 min.
The DTE-processed samples were used to make cytospins
(450 rpm for 6 min) for total and differential cell counts, 400
non-squamous cells were calculated. The slides were frozen
at -20°C until analysis. The supernatant was frozen at -80°C
for biochemical analysis and immunoassay.
8-isoprostane analysis
8-Isoprostane (8-iso-PGF2 α) concentrations in induced
sputum samples were determined by specific enzyme
immunoassay (EIA) kit (Cayman Chemical, Ann Arbor,
MI, USA) with standard curves using purified 8-isopros-
tane. The sputum samples were diluted in the EIA buffer
provided by the manufacturer and analysed as recently
described and tested by our group [8]. Values were
expressed as pg/ml.
Exhaled NO measurement
The FeNO measurements (Niox; Aerocrine AB, Sweden)
were performed according to the ATS guidelines [20].
Expiratory airflow was 50 ml/s against a flow resistor, with
an exhalation time of 10 sec. The mean value from a 3-sec-
ond period from the end-exhaled NO plateau was
recorded. At least three successive FeNO measurements
were performed and the mean value was used for analysis.
Immunocytochemical analysis of sputum cells
Nitrotyrosine (NT) was assessed by immunocytochemis-
try by counting the NT-positive cells from amongst a total
of 400 cells counted in every cytospin. Polyclonal nitroty-
rosine antibody (Upstate Lake Placid, NY, US) in 1:100
dilution and the Zymed Broad spectrum antibody (Zymed
Laboratories Inc., South San Francisco, CA, USA) as the
secondary antibody were used as described by Rytilä et al
[9]. The Zymed ABC Histostain-Plus Kit (Zymed Labora-
tories Inc.) was used according to the manufacturer's pro-
tocol to identify positively stained cells.
Measurement of MMP-8
MMP-8 was determined by commercially available ELISA
kit (Amersham Biosciences, Cardiff, UK) according to the
manufacturer's instructions.
Statistical analysis
All statistical analyses were performed using the SPSS 10.0
software program (SPSS Inc., Chicago, IL). As the data
were not normally distributed, non-parametric tests were
used for all comparisons. Data for individual variables
from the several groups were first analyzed by the Kruskal-
Wallis test followed by the Mann-Whitney U-test. All dif-
ferences within sets of paired data were analysed by the
non-parametric Wilcoxon signed rank test. We accepted p
values of <0.05 as significant.
Results
Spirometry values (FVC, FEV1, FEV/FVC) did not change
significantly after smoking cessation when compared to
baseline in any of the groups, reasons include the short
follow-up and the fact that most participants were
"healthy smokers", had chronic bronchitis/COPD or mild
asthma. In the group of chronic bronchitis/COPD the per-
centage of sputum neutrophils increased significantly
after 3 months of smoking cessation (p = 0.046) (Fig 1),
while the cell counts remained similar in the asympto-
matic (healthy) smokers and the asthmatics.
The baseline values of the 3 oxidant markers and MMP-8,
investigated in the 3 study groups, in comparison to the
values in non-smokers/ex smokers (over 20 years after
smoking cessation) are presented in Figs 2, 3, 4 and 5. The
values of non-smokers have been published in the recent
studies of our laboratory with similar sputum processing
and analyses [8,9,15,21,22] and contain pooled data both
from never smokers (n = 20) and ex-smokers who had
stopped >20 years ago (n = 12); altogether six control
specimens were re-analyzed for the current study showing
very similar levels as in those earlier investigations. As
shown in Figs 2, 3, 4 and 5, the levels of all markers were
significantly lower (p < 0.001 for each marker) in non-
smokers than in smokers. However, the markers did not
differ significantly between the asymptomatic smokers,
smoking asthmatics or smokers with chronic bronchitis/
COPD.
Given the relatively small number of cases in each group
and the overlap between the values, the results of the 3BMC Pulmonary Medicine 2009, 9:25 http://www.biomedcentral.com/1471-2466/9/25
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month longitudinal study were combined into one analy-
sis as presented in Fig 6, 7, 8 and 9. In this combined
group, only sputum 8-isoprostane changed significantly
during the follow-up at 3 months (p = 0.035). The change
of isoprostane at one month was not significant although
a trend to decrease could be detected (p = 0.07). The levels
of 8-isoprostane remained higher than in non-smokers
after 3 months of smoking cessation (see Fig 3). FeNO
and nitrotyrosine positive sputum cells showed no ten-
dency to change. There was a trend for MMP-8 to decline
after smoking cessation, but the levels also remained
higher than in non-smokers (see Fig 5).
Symptoms assessed by the St Georges Respiratory Ques-
tionnaire (SGRQ) improved significantly (over four
points based on the SGRQ manual) in those subjects who
quitted smoking, especially at the one month visit but
were still lower at three months when compared to the
beginning of the study. Improvement was seen in all parts
of the questionnaire: symptoms, activity and impact
scores (Table 2).
Sputum neutrophils (%) in the induced sputum of the sub- jects with bronchitis and COPD Figure 1
Sputum neutrophils (%) in the induced sputum of the 
subjects with bronchitis and COPD. P-value was calcu-
lated with Wilcoxon signed rank test. P = 0.046.
Fractional exhaled nitric oxide (FeNO) in bronchitis and  COPD patients (COPD), asthmatics (A) and asymptomatic  smokers (S) at the beginning of the study Figure 2
Fractional exhaled nitric oxide (FeNO) in bronchitis 
and COPD patients (COPD), asthmatics (A) and 
asymptomatic smokers (S) at the beginning of the 
study. The values of non smokers (NS) have been gathered 
from previously published materials where non-smokers 
were combined from two groups of subjects i.e. never smok-
ers and ex smokers who had quitted smoking over 20 years 
ago. The levels of each marker in these two groups of non-
smokers have been found to be very similar [8,9,15,20]. P-
value was calculated with Kruskall-Wallis test.
Levels of sputum 8-isoprostane in bronchitis and COPD  patients (COPD), asthmatics (A) and asymptomatic smokers  (S) at the beginning of the study Figure 3
Levels of sputum 8-isoprostane in bronchitis and 
COPD patients (COPD), asthmatics (A) and asymp-
tomatic smokers (S) at the beginning of the study. 
The values of non smokers (NS) have been gathered from 
previously published materials where non smokers were 
combined from two groups of subjects i.e. never smokers 
and ex smokers who had quitted smoking over 20 years ago. 
The levels of each marker in these two groups of non-smok-
ers have been found to be very similar [8,9,15,20]. P-value 
was calculated with Kruskall-Wallis test.
Levels of sputum nitrotyrosine (% of positive cells) in bron- chitis and COPD patients (COPD), asthmatics (A) and  asymptomatic smokers (S) at the beginning of the study Figure 4
Levels of sputum nitrotyrosine (% of positive cells) in 
bronchitis and COPD patients (COPD), asthmatics 
(A) and asymptomatic smokers (S) at the beginning 
of the study. The values of non smokers (NS) have been 
gathered from previously published materials where non-
smokers were combined from two groups of subjects i.e. 
never smokers and ex smokers who had quitted smoking 
over 20 years ago. The levels of each marker in these two 
groups of non-smokers have been found to be very similar 
[8,9,15,20]. P-value was calculated with Kruskall-Wallis test.BMC Pulmonary Medicine 2009, 9:25 http://www.biomedcentral.com/1471-2466/9/25
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Discussion
Smoking cessation still remains the best therapeutic inter-
vention in smokers, especially in individuals who have
evidence of COPD or asthma [23]. Despite major efforts
in developing cessation programs and drugs to ease the
process, success rates are generally low to moderate [24-
26]. In our study 25% of the smokers succeeded in quit-
ting of smoking at least for the time of the follow-up, a
success rate which is good and close to the published
results of programs involving COPD patients who had
received active counseling [27]. Understanding the mech-
anisms whereby quitting smoking leads to better health is
important not only for a better understanding of disease
mechanisms but also to obtain relevant information
which can be presented to patients in order to encourage
them not to go back to smoking which, according to cur-
rent evidence, happens to a large proportion of patients.
Levels of sputum MMP-8 in bronchitis and COPD patients  (COPD), asthmatics (A) and asymptomatic smokers (S) at  the beginning of the study Figure 5
Levels of sputum MMP-8 in bronchitis and COPD 
patients (COPD), asthmatics (A) and asymptomatic 
smokers (S) at the beginning of the study. The values 
of non smokers (NS) have been gathered from previously 
published materials where non smokers were combined 
from two groups of subjects i.e. never smokers and ex smok-
ers who had quitted smoking over 20 years ago. The levels of 
each marker in these two groups of non-smokers have been 
found to be very similar [8,9,15,20]. P-value was calculated 
with Kruskall-Wallis test.
Levels of sputum 8-isoprostane in the combined groups of  chronic bronchitis and COPD (COPD), asthma (A) and  asymptomatic smokers (S) Figure 6
Levels of sputum 8-isoprostane in the combined 
groups of chronic bronchitis and COPD (COPD), 
asthma (A) and asymptomatic smokers (S). Individual 
subgroups are presented as corresponding symbols and 
shown in the panels. Only 8-isoprostane in the combined 
group showed a significant decline (p = 0.035) after smoking 
cessation calculated with Wilcoxon signed rank test. The 
number of the analyses was lower than the total number of 
subjects who succeeded in smoking cessation due to unrep-
resentative sputum specimen during the control visit.
Exhaled fractional nitric oxide (FeNO) in the combined  groups of chronic bronchitis and COPD (COPD), asthma (A)  and asymptomatic smokers (S) Figure 7
Exhaled fractional nitric oxide (FeNO) in the com-
bined groups of chronic bronchitis and COPD 
(COPD), asthma (A) and asymptomatic smokers (S). 
Individual subgroups are presented as corresponding symbols 
and shown in the panels. Only 8-isoprostane in the combined 
group showed a significant decline (p = 0.035) after smoking 
cessation calculated with Wilcoxon signed rank test. The 
number of the analyses was lower than the total number of 
subjects who succeeded in smoking cessation due to unrep-
resentative sputum specimen during the control visit.
Percentage of nitrotyrosine positive cells in the combined  groups of chronic bronchitis and COPD (COPD), asthma (A)  and asymptomatic smokers (S) Figure 8
Percentage of nitrotyrosine positive cells in the com-
bined groups of chronic bronchitis and COPD 
(COPD), asthma (A) and asymptomatic smokers (S). 
Individual subgroups are presented as corresponding symbols 
and shown in the panels. Only 8-isoprostane in the combined 
group showed a significant decline (p = 0.035) after smoking 
cessation calculated with Wilcoxon signed rank test. The 
number of the analyses was lower than the total number of 
subjects who succeeded in smoking cessation due to unrep-
resentative sputum specimen during the control visit.BMC Pulmonary Medicine 2009, 9:25 http://www.biomedcentral.com/1471-2466/9/25
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Our study shows that oxidative stress can persist even
three months after patients stop smoking. Contrary to
what was anticipated, but in agreement with previous
results, neutrophil counts increased in COPD after smok-
ing cessation [6]. Published evidence suggests that inflam-
mation continues after smoking cessation, although there
have been no thorough longitudinal studies of how long
inflammation persists and whether it is definitely irrevers-
ible. Cross-sectional studies have shown elevated inflam-
matory indices in terms of macrophages, neutrophils and
eosinophils in ex-smokers when compared to never
smokers [28-31], and a shift from CD4+ (T-helper) to
CD8+ (T-suppressor) predominance in heavy smokers
and COPD [7,32]. There have been only few prospective
longitudinal studies comparing indices of inflammation
before and after smoking cessation [5,6], but no studies
have been conducted on markers of oxidative/nitrosative
stress after smoking cessation. Our results confirm previ-
ous findings that airway inflammation persists after
smoking cessation for months. Whilst this study shows
that there is some decline in oxidative stress (as suggested
by the decline in 8-isoprostane), the ongoing oxidant and
protease load is seen months after smoking cessation.
Given that COPD is also systemic disease further studies
are needed to assess how the biomarkers that reflect sys-
temic oxidative stress/inflammation will be changed after
smoking cessation. Importantly, symptoms declined sig-
nificantly already one month after patients stopped smok-
ing underlining the complexity of multiple consequences
related to smoking cessation.
Studies on asthma have to date concentrated on non-smok-
ing subjects in order to avoid the known effects of smoking
confounding the pathogenic mechanisms under investiga-
tion. Cigarette smoking in adults with established asthma is
associated with increased symptom severity and exacerba-
tion frequency [4], accelerated decline in lung function [33]
and impaired response to inhaled and oral corticosteroids
[34-36], features which are associated with COPD. In addi-
tion to having eosinophilic airway inflammation normally
observed in asthma, asthmatic smokers have neutrophilic
inflammation [37], a further feature that is typical of COPD.
However, there is limited knowledge of the effects of smok-
ing on asthmatic airway inflammation. In the study of
Chaudhuri et al. [5] sputum neutrophil counts decreased
after 6 weeks of smoking cessation, which is in contrast with
our observation as we saw no significant changes in neu-
trophils during the three months after smoking cessation in
the asthmatics. Although the number of asthmatics was low,
the results exclude dramatic improvements in airway inflam-
mation after smoking cessation in asthma.
Looking at the bronchitis/COPD group alone, the per-
centage of sputum neutrophils increased significantly
after 3 months of smoking cessation in bronchitis/COPD.
Whilst these results have to be interpreted with caution
because of low subject numbers, together with results
from a previous study of 12 COPD patients and 16
asymptomatic smokers [6], which showed high neu-
trophil counts one year after smoking cessation, this
would suggest that neutrophilic inflammation does not
subside long after subjects stop smoking.
Levels of sputum MMP-8 in the combined groups of chronic  bronchitis and COPD (COPD), asthma (A) and asympto- matic smokers (S) Figure 9
Levels of sputum MMP-8 in the combined groups of 
chronic bronchitis and COPD (COPD), asthma (A) 
and asymptomatic smokers (S). Individual subgroups are 
presented as corresponding symbols and shown in the pan-
els. Only 8-isoprostane in the combined group showed a sig-
nificant decline (p = 0.035) after smoking cessation calculated 
with Wilcoxon signed rank test. The number of the analyses 
was lower than the total number of subjects who succeeded 
in smoking cessation due to unrepresentative sputum speci-
men during the control visit.
Table 2: Symptoms score
Visit Symptoms score Activity score Impact score Total score
0 47 (0–91) 39 (0–100) 19 (0–69) 30 (2–82)
1 16 (0–53) 18 (0–61) 4 (0–38) 10 (0–41)
3 26 (0–77) 18 (0–55) 14 (0–43) 21 (0–61)
Symptoms score is concerned with the effect of respiratory symptoms, their frequency and severity, activity score activities that cause or are 
limited by breathlessness and impacts score covers a range of aspects such as social functioning and psychological disturbances resulting from 
airways disease. Total score summarises the impact of the disease on overall health status. According to SGRQ manual, decrease of more than four 
points in the questionnaire is clinically significant. SGRQ total score and subdomains scores are given only for the quitters.BMC Pulmonary Medicine 2009, 9:25 http://www.biomedcentral.com/1471-2466/9/25
Page 7 of 9
(page number not for citation purposes)
8-isoprostane was studied as a potential marker of ongo-
ing oxidative stress in lung diseases [38] that is reliably
detected in in vivo specimens [39]. It has been suggested to
be a specific marker for lipid peroxidation [40] and is sen-
sitive in evaluating oxidative/nitrosative stress in the air-
ways. Furthermore, it is stable, allowing determination in
frozen specimens [38]. Increased levels of 8-isoprostane
have been previously measured in sputum samples of sta-
ble COPD [8] and mild/moderate/severe asthma when
compared to healthy controls [21,41], although levels
have been highly variable. 8-isoprostane has also been
detected and shown to be elevated in the exhaled breath
condensate in many lung diseases [42-45] and confirmed
by reference analytical techniques by Montuschi and co-
workers [46].
Smoking alone increases levels of sputum 8-isoprostane
when compared to non-smoking controls [8]. In the
present study the baseline levels of 8-isoprostane were
already highly variable especially in the asthmatics. When
the results from three groups were combined the levels of
8-isoprostane in the individual subgroups declined signif-
icantly after smoking cessation, but remained higher than
in non-smokers (Figs 2, 3, 4, 5, 6, 7, 8 and 9). Overall, the
present results suggest that there is clear trend but no
major or immediate decline in the oxidative stress within
the first months after smoking cessation when evaluated
by sputum 8-isoprostane.
Fractional nitric oxide (FeNO) is elevated in inflamma-
tory diseases such as asthma [47], especially in atopic
asthma and the elevation is generally limited to steroid-
naïve asthmatics. It is one of the few non-invasive markers
that have been used in the clinical assessment of asth-
matic patients [48]. FeNO is decreased by cigarette smoke
but most studies suggest that FeNO is not significantly dif-
ferent from normal in stable COPD [9,49-51]. To our
knowledge, FeNO has not been investigated in longitudi-
nal studies after smoking cessation. Based on past investi-
gations which have shown FeNO to decrease in smokers
[9,52], it can be speculated that FeNO might increase after
smoking cessation. Our recent cross-sectional study
showed levels of FeNO to be approximately 11 pbb in
healthy smokers and 22 pbb in non-smokers [9]. In the
present study FeNO was highly variable in asthma, possi-
ble reasons being not only the extent of smoking but also
variable severity and usage of inhaled corticosteroids;
each asthmatic was on inhaled steroids, which were not
changed during the course of this study. FeNO appeared
to be moderately variable in bronchitis/COPD but in both
groups it remained unchanged after smoking cessation.
Exact comparisons are difficult because all patients with
asthma in this study were on inhaled steroids, whereas
most of the patients with COPD were not. Overall,
unchanged FeNO levels suggest that oxidative/nitrosative
stress does not change markedly during 3 months after
smoking cessation. Moreover, the regulation of FeNO is
complex, and many reactions associated with its changes
in smoking asthmatics and COPD patients are still incom-
pletely understood and difficult to interpret in real life.
The final marker of oxidative stress investigated was nitro-
tyrosine which has been suggested to play a major role in
the pathogenesis of airway remodelling [53]. Numerous
nitrotyrosine positive sputum cells have been seen not
only in COPD [54] but also in current cigarette smokers
without airway obstruction [9]. Nitrotyrosine positive
sputum cell counts are elevated in healthy smokers when
compared to never smokers [9], with further increases in
COPD [54]. The numbers of nitrotyrosine positive cells in
the sputum remained unchanged after smoking cessation
for 3 months, which is in agreement with the results
obtained with other markers of oxidative/nitrosative
stress. It is apparent that smoking cessation does not lead
to any immediate changes in the oxidant burden in
asthma or COPD. This may be associated with the persist-
ence of ongoing inflammation and possibly also with the
activation status of the inflammatory cells.
Several MMPs including MMP-8, MMP-9 and MMP-12
have been associated with COPD [10]; in our recent study
only the levels of MMP-8 were higher in chronic bronchi-
tis compared to asymptomatic smokers [15]. Since oxida-
tive stress and cigarette smoke associated oxidants may
also enhance MMP activation, it can be speculated that the
levels of MMPs might decrease after smoking cessation. In
the present study MMP-8 levels showed some tendency to
decrease but there was a high individual variation in the
MMP-8 levels after 3 months quitting of smoking. The lev-
els of MMP-8 in bronchitis/COPD after stopping of smok-
ing at 3 months were still much higher than in non-
smokers as measured in our recent study [15] (see also Fig
2, 3, 4 and 5). These results suggest persistence of the pro-
tease cascade imbalance months after smoking cessation.
The current study has a number of limitations; the most
important being is the modest success of the smoking ces-
sation and the short follow-up. The success rate of smok-
ing cessation was also very different between the groups,
which may be explained by differences in smoking cessa-
tion programs, including clinical care setting, the use of
smoking cessation aids e.g drugs and the intensity of
counselling. Another limitation is the variability of the
subject characteristics and medications within the groups.
COPD group also included subjects with symptoms of
chronic bronchitis. The use of steroids differed between
the groups, though the use in individual subjects was the
same at the baseline and in the control visit. However, oxi-
dant markers varied even more inside the asthma group
than in the bronchitis/COPD group. These realities reduce
the statistical power of our analyses. The variability in
inflammatory/oxidant markers in sputum specimens wasBMC Pulmonary Medicine 2009, 9:25 http://www.biomedcentral.com/1471-2466/9/25
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also reported in a recent study of Sapey et al who exam-
ined several cytokines and oxidants in spontaneous spu-
tum samples from patients with COPD; that particular
study revealed high cytokine variability in consequent
sputum specimens even in stable COPD [55].
One final important finding of the present study is the
decline in symptoms despite persistent neutrophilic airway
inflammation and oxidative stress. Symptoms already
reduced one month after smoking cessation, when none of
the other markers had yet declined significantly. This finding
is important and suggests that clinical improvement does
not necessarily correlate with objective assessment of
asthma/COPD or that these biomarkers may not be the best
ones in regard to clinical relevance in COPD and/or that the
mechanisms of COPD are still poorly known. Such discrep-
ancies have, however, been found in many clinical trials
where symptom score but not objective monitoring of the
disease reveals significant improvement within the first
months of treatment. Whilst our study suggests that smoking
cessation overall does not cause any major immediate
decline in the oxidant burden in COPD or asthma, the wide
individual variability in the outcomes measured raises the
questions as to whether some of these markers may be pre-
dictive of which patient goes on to develop further lung
damage and in which patient the disease processes may be
arrested. It is possible that the participants' assessment of
their symptoms was influenced by their positive perception
of successful cessation of smoking and further studies in
which this confounding factor is controlled for are needed.
Further studies are also needed to investigate the specific
pathways that may remain activated after smoking cessation
and the development of new antioxidant/redox modulatory
and/or protease inhibitor strategies directed to these path-
ways also after smoking cessation.
Conclusion
There are only a few studies about the effects of smoking
cessation on oxidant markers in the longitudinal setting.
We investigated whether smoking cessation has effects on
sputum markers of oxidative/nitrosative stress in exhaled
air and sputum of subjects with chronic bronchitis/
COPD, asthma and asymptomatic smokers during a
period of 3 months after quitting smoking. Sputum neu-
trophils increased after smoking cessation in patients with
chronic bronchitis/COPD, but the levels of FeNO, nitroty-
rosine and MMP-8 did not change significantly during the
3 months after smoking cessation in any of the groups.
Symptoms decreased significantly in those subjects who
quitted smoking. We conclude that although symptoms
improve after smoking cessation, the oxidant and pro-
tease burden in the airways continues at least for months.
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